A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
OBJECTIVES: This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in the treatment of rheumatoid arthritis (RA) in adults. DATA SOURCES: Electronic databases were search...
Auteurs principaux: | Chen, Y, Jobanputra, P, Barton, P, Jowett, S, Bryan, S, Clark, W, Fry-Smith, A, Burls, A |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2006
|
Documents similaires
-
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
par: Chen, Y, et autres
Publié: (2006) -
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
par: Jobanputra, P, et autres
Publié: (2002) -
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
par: Jobanputra, P, et autres
Publié: (2002) -
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
par: P. Jobanputra, et autres
Publié: (2002-01-01) -
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
par: K Malottki, et autres
Publié: (2011-03-01)